Collaboration Is the X Factor in Making Precision Medicine a Success

Last year, the FDA approved 59 new molecular entities for the US market, the highest number ever approved in a single year. A key driver of this record level of approvals is the explosive growth of precision medicine. Since 2015, at least a fifth of all new drug approvals each year have been precision therapies and in 2018 they accounted for nearly half (42 percent).
Read more...

;